ABSTRACT This study shows the case of a 20-year-old male patient diagnosed withmultiple sclerosis (MS) at the age of 13, who developed retinalhemorrhage after six years of treatment with fingolimod. The case reportwas prepared based on information collected from the patient’s medicalrecords, with proper authorization. The case highlights the sustainedefficacy of fingolimod in controlling the disease throughout thetreatment period. However, the observed ocular event, in associationwith other reported adverse events, prompted a reassessment of thetherapeutic approach.